Project 3: Epidemiological and Clinical Translational Studies Post Genome-Wide Association (GWAS) Project Leader: Rosalind Eeles Project Summary: The main focus of Project 3 is establishing a transdisciplinary collaborative network comprised of clinical scientists, epidemiologists, geneticists, and biostatisticians focusing on the transition from 'bench-side'research to 'bed-side'care. The CEC (Clinical ELLIPSE Consortium) will harmonize genetic, clinical, and environmental data from existing consortia, with over 35,000 prostate cancer cases, to evaluate gene, genegene, and gene-environmental effects on prostate cancer risk, including aggressive disease, recurrence, and mortality. The highly integrated ELLIPSE projects will facilitate the most up to date genetic evaluation by working closely with Project 1, identifying novel genetic candidates, and Project 2, providing biological insights on function. The assessment of genetic and environmental interactions will be evaluated for inclusion into a risk score as well as potentially providing directional input for Projects 1 and 2. All risk evaluations will be assessed in European, African American, and Japanese populations. Finally, this initial stage will provide the necessary guidance in developing useful and powerful risk prediction models for prostate cancer risk, including screening, outcome and treatment effects. These risk prediction models may have an immediate public health impact by providing clinicians with the necessary tools to improve clinical-decision making.
The main focus of this project is to establish a transdisciplinary network of highly innovative scientists investigating the impact of genetic, environmental, and effect modifiers (ie gene-gene and gene-environment) on prostate cancer risk in a multiethnic sample. In particular, this project will initiate the process the of going from the 'bench-side'to the 'bed-side'by developing risk prediction models needed in prostate cancer prediction, screening, progression, and treatments.
|Han, Ying; Signorello, Lisa B; Strom, Sara S et al. (2015) Generalizability of established prostate cancer risk variants in men of African ancestry. Int J Cancer 136:1210-7|
|Agarwal, D; Pineda, S; Michailidou, K et al. (2014) FGF receptor genes and breast cancer susceptibility: results from the Breast Cancer Association Consortium. Br J Cancer 110:1088-100|
|Al Olama, Ali Amin; Kote-Jarai, Zsofia; Berndt, Sonja I et al. (2014) A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. Nat Genet 46:1103-9|
|Lindström, Sara; Thompson, Deborah J; Paterson, Andrew D et al. (2014) Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. Nat Commun 5:5303|
|Pooley, Karen A; McGuffog, Lesley; Barrowdale, Daniel et al. (2014) Lymphocyte telomere length is long in BRCA1 and BRCA2 mutation carriers regardless of cancer-affected status. Cancer Epidemiol Biomarkers Prev 23:1018-24|
|Hazelett, Dennis J; Rhie, Suhn Kyong; Gaddis, Malaina et al. (2014) Comprehensive functional annotation of 77 prostate cancer risk loci. PLoS Genet 10:e1004102|
|Andreassen, Ole A; Zuber, Verena; Thompson, Wesley K et al. (2014) Shared common variants in prostate cancer and blood lipids. Int J Epidemiol 43:1205-14|
|Eeles, Rosalind; Goh, Chee; Castro, Elena et al. (2014) The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol 11:18-31|
|Milne, Roger L; Burwinkel, Barbara; Michailidou, Kyriaki et al. (2014) Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. Hum Mol Genet 23:6096-111|
|Li, Jingmei; Lindström, Linda S; Foo, Jia N et al. (2014) 2q36.3 is associated with prognosis for oestrogen receptor-negative breast cancer patients treated with chemotherapy. Nat Commun 5:4051|
Showing the most recent 10 out of 40 publications